Market Research Reports, Inc.

MarketResearchReports.Com: Major Depressive Disorder: 5EU Drug Forecast and Market Analysis to 2023, New Report Launched

Market Research Reports, Inc. has announced the addition of “PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023 research report to their website http://www.marketresearchreports.com

 
Repost This

Lewes, DE -- (SBWIRE) -- 06/23/2014 -- Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly’s Cymbalta, and Otsuka/BMS’s Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda’s Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

The value of the depression market in France is expected to fall following patent expiries for Lundbeck’s Lexapro in 2014, Eli Lilly’s Cymbalta in 2014, Otsuka Pharmaceutical/BMS’s Abilify in 2014, and AstraZeneca’s Seroquel XR in 2017. Publisher estimates the drug sales for MDD in Germany were approximately $236.7m in 2013. Publisher expects Eli Lilly’s Cymbalta and Lundbeck’s Brintellix to be the top-selling products by the end of the forecast period in Italy. Publisher anticipates seven products in the late-stage pipeline to enter the MDD market in Spain during the forecast period: four adjunctive therapies, and three other antidepressant therapies. If physicians in the UK become convinced from experience in clinical practice that Brintellix offers improvements in cognitive function, Lundbeck will be able to differentiate Brintellix from other available SSRI and SNRI treatments and subsequently drive higher patient share.

Spanning over 193 pages, “PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023” report covering the Disease Overview, Disease Management, Competitive Assessment, Unmet Needs and Opportunities, Pipeline Assessment, Market Outlook, Appendix.

For more information see - http://www.marketresearchreports.com/globaldata/pharmapoint-major-depressive-disorder-5eu-drug-forecast-and-market-analysis-2023

Find all Healthcare Reports at : http://www.marketresearchreports.com/healthcare

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Follow us on Vimeo : http://vimeo.com/marketresearchreports